We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.
- Authors
Peffault de Latour, R; Asselah, T; Lévy, V; Scieux, C; Devergie, A; Ribaud, P; Espérou, H; Traineau, R; Gluckman, E; Valla, D; Marcellin, P; Socié, G
- Abstract
We recently reported an increased incidence of cirrhosis in hepatitis C virus (HCV)-infected stem cell transplant (SCT) recipients. Here, we describe our experience in the treatment of these patients, which has been, to date, poorly reported in the literature. Among 99 HCV-infected HCT recipients, 36 had HCV-related liver lesions on biopsy requiring therapy. Owing to HCV treatment contraindications, only 61% of patients (22/36) could be treated. In all, 12 patients received more than one course of anti-HCV treatment if they had HCV RNA still detectable after the first course of treatment and no treatment contraindications. Combined therapy (pegylated interferon (IFN): n=9, or standard IFN: n=9, in combination with ribavirin) led to sustained virological response in 4/18 (20%) patients as compared to 2/20 (10%) in patients who received IFN alone. Hematological toxicity was more frequent with combined therapy. While anemia responded to erythropoietin and/or dose modification, thrombocytopenia usually led to treatment interruption (n=3). This study thus highlights the efficacy of combined therapy and emphasizes the fact that the undue safety concerns are not a problem when treating this particular population.
- Publication
Bone marrow transplantation, 2005, Vol 36, Issue 8, p709
- ISSN
0268-3369
- Publication type
Journal Article
- DOI
10.1038/sj.bmt.1705120